AbbVie (NYSE: ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and ...
Michaels is fueling the joy of creativity and celebration with the release of its annual Creativity Trend Report, declaring 2026 the Year of Creative Living in the analog era. Launched in tandem with ...
New data shows a pivot toward hands-on rituals and skill-building as consumers swap screen time for self-discovery and tangible connection ...
Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-valueAt the maximally effective dose, there were no cases of vomiting and no treatment ...
A once-weekly amylin analog conferred up to 10.7% weight loss at 42 weeks among adults with overweight or obesity and featured a safety profile similar to placebo, according to topline results from ...
Georgia lawmakers face a midnight deadline on Crossover Day as key bills on income tax and data centers move forward while ...
Children and adolescents with diabetes using inhaled insulin had an increase in HbA1c from baseline to 1 year, according to data from the INHALE-1 extension trial published in Diabetes Technology & ...
Shabana Azeez discusses the deeper meaning behind Javadi's breakdown in The Pitt Season 2, and how it reflects the pressures ...
Petrelintide achieved up to 10.7% mean body weight reduction at week 42 (versus 1.7% with placebo) and demonstrated placebo-like tolerability At the maximally effective dose, there were no cases of ...
In just a few short years, Revel Bikes has gone from relative obscurity to building bikes that consistently punch above their ...
Nostalgia has a funny way of making us believe that the past was better than it actually was. We look back through a haze of fond memories, often glossing over the tough realities of those “simpler” ...
Gubra's partner AbbVie today announced positive topline results from the 12 and 13-weeks Phase 1 Multiple Ascending Dose (MAD) trial showing that ABBV-295 was well tolerated with a dose-dependent sign ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results